Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol

Journal of Clinical Oncology

Volumn 18, Issue 11, 2000, Pages 2301-2308

  Yamamoto, Noboru ^a   Tamura, Tomohide ^a   Kamiya, Yoshikazu ^a   Sekine, Ikuo ^a   Kunitoh, Hideo ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; DOCETAXEL; HYDROCORTISONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0034120413     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.11.2301     Document Type: Article

References (42)

1. Nelson DR, Koymans L, Kamataki T, et al: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42, 1996
2. Lin JH, Lu AYH: Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390, 1998
3. Parkinson A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45-57, 1996
4. Guengerich FP: Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 29:241-264, 1989
5. Guengerich FP, Turvy CG: Comparison of levels of human microsomal cytochrome P450 enzymes and epoxide hydrolase in normal and disease status using immunochemical analysis of surgical samples. J Pharmacol Exp Ther 256:1189-1194, 1991
6. Hunt CM, Westerkam WR, Stave GM: Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275-283, 1992
7. Watkins PB, Turgeon DK, Saenger P, et al: Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 52:265-273, 1992
8. Kinirons MT, O'Shea D, Downing TE, et al: Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54:621-629, 1993
9. Hunt CM, Watkins PB, Saenger P, et al: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51:18-23, 1992
10. Bienvenu T, Rey E, Pons G, et al: A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther 29:441-445, 1991
11. Ohnhaus EE, Park BK: Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 15:139-145, 1979
12. Ohnhaus EE, Breckenridge AM, Park BK: Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 36:39-46, 1989
13. Ged C, Rouillon JM, Pichard L, et al: The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28:373-387, 1989
14. Hudis CA, Seidman AD, Crown JP, et al: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
15. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 14:422-428, 1996
16. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
17. Ravdin PM, Burris HR, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
18. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
19. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
20. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
21. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J Natl Cancer Inst 83:288-291, 1991
22. Taguchi T, Furue H, Niitani H, et al: Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho 21:1997-2005, 1994
23. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 11:950-958, 1993
24. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976: NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
25. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1994
26. Marre F, Sanderink GJ, de Sousa G, et al: Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302, 1996
27. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
28. Nakamura J, Yakata M: Determination of urinary cortisol and 6 beta-hydroxycortisol by high performance liquid chromatography. Clin Chim Acta 149:215-224, 1985
29. Lykkesfeldt J, Loft S, Poulsen HE: Simultaneous determination of urinary free cortisol and 6 beta-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B Biomed Appl 660:23-29, 1994
30. Vergniol JC, Bruno R, Montay G, et al: Determination of Taxotere in human plasma by a semi-automated high-performance liquid Chromatographic method. J Chromatogr 582:273-278, 1992
31. Bruno R, Vivier N, Vergniol JC, et al: A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. J Pharmacokinet Biopharm 24:153-172, 1996
32. Tanigawara Y, Sasaki Y, Ohtsu T, et al: Population pharmacokinetics of docetaxel in Japanese patients. Proc Am Soc Clin Oncol 15:479a, 1996 (abstr 1518)
33. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
34. Watkins PB, Murray SA, Winkelman LG, et al: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: Studies in rats and patients. J Clin Invest 83:688-697, 1989
35. Watkins PB, Hamilton TA, Annesley TM, et al: The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 48:120-129, 1990
36. Lown K, Kolars J, Turgeon K, et al: The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51:229-238, 1992
37. Fleming CM, Branch RA, Wilkinson GR, et al: Human liver microsomal N-hydroxylation of dapsone by cytochrome. Mol Pharmacol 41:975-980, 1992
38. May DG, Arns PA, Richards WO, et al: The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 51:689-700, 1992
39. May DG, Porter J, Wilkinson GR, et al: Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 55:492-500, 1994
40. Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 17:305-313, 1993
41. Cortes JE, Pazdur R: Docetaxel, J Clin Oncol 13:2643-2655, 1995
42. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:1781-1788, 1992